Data as of 3:59pm ET
| -0.015 / -0.57%|
The 4 analysts offering 12-month price forecasts for Pluristem Therapeutics Inc have a median target of 5.50, with a high estimate of 8.00 and a low estimate of 3.50. The median estimate represents a +110.73% increase from the last price of 2.61.
The current consensus among 4 polled investment analysts is to Buy stock in Pluristem Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.